Blockchain Registration Transaction Record

ABVC Subsidiary AiBtl Secures Strategic Land Acquisition Agreement in Taiwan for Botanical Drug Production

ABVC BioPharma's subsidiary, AiBtl, secures a strategic land acquisition agreement in Taiwan for botanical drug production, reinforcing the company's commitment to innovation in CNS treatments. The move aims to reduce sourcing risk and support large-scale production of active botanical compounds for MDD and ADHD treatments, signaling a significant step towards revolutionizing the treatment landscape in neurology.

This news matters as it highlights ABVC's proactive approach to securing upstream resources for its drug development pipeline, addressing substantial market demands for innovative treatments in neurological disorders. The strategic move not only enhances the company's value for shareholders but also signifies a long-term commitment to sustainable botanical drug innovation, potentially revolutionizing the treatment landscape for Major Depressive Disorder and ADHD.